Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

BeiGene's BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended ... out with bendamustine plus rituximab, or dexamethasone plus rituximab and cyclophosphamide.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further ...

Early infection incidence in patients with multiple myeloma following treatment with cilta-cel infusion highlights the ...

Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial ...

Acute respiratory distress syndrome (ARDS) continues to be a tough nut to crack in critical care, taking lives despite years of research and better ventilator strategies. It is defined by acute ...

Acute respiratory distress syndrome (ARDS) continues to be a tough nut to crack in critical care, taking lives despite years of research and better ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

Benefits advisors need to stay proactive and help their clients leverage formulary design, clinical oversight, and ...